• Home
  • Service
  • NeXST SVC
  • Notice: Undefined variable: sub_code in /home/host/nexelshop/www/html/_skin/mdp/layout/inc_path.php on line 79
  • Overview

NeXST SVC Overview

Cardiac safety (Predicting proarrhythmic risk of investigational drugs)

Evaluating the effects of drugs on multi-ion channels in the cardiomyocytes.
Providing accurate prediction of proarrhythmic risk (TdP, Torsade de Pointes) of investigational drugs in accordance with the CiPA-initiated assessment method of new ICH Guideline.
* ISO17025 certified.

Applications:

* Proarrhythmic risk screening at early drug discovery (hit to lead).
* Optimal dose screening for preclinical study.
* Cardiac safety pharmacology study for IND filing of investigational drugs (after adoption of new ICH E14/S7B).

Cardiac contractility

Providing real contractility measurement upon drug treatments from functional cardiomyocytes.

Applications:

* Screening the drug-induced cardiac contractile force changes (Investigational drugs from hit to preclinical stages)
* Efficacy and toxicity evaluation

Skeletal muscle contractility

Providing clinically-relevant functional data by measuring real contractile force of 3D engineered skeletal muscle tissues.

Applications:

* Screening the drug-induced skeletal muscle contractile force changes (Investigational drugs from hit to preclinical stages)
* Efficacy and toxicity evaluation

Calcium transient

Providing surrogate evidence of intracellular calcium level changes upon drug treatment.

Applications:

* Screening the drug-induced calcium transient changes (Investigational drugs from hit to preclinical stages)

Lung toxicity

Human iPSC-derived AECs(Alveolar Epithelial Cells) are phenotypically and functionally resembled primary AECs and biologically relevant for pulmotoxic assessment.
Using the iPSC-derived AECs(Alveolar Epithelial Cells)-organoids for evaluation on functional effects of drugs is more clinically-relevant approach.

Applications:

* Potential lung toxicity screening at early drug discovery (hit to lead).
* Optimal dose screening for preclinical study.

Lung fibrosis

Providing anti-fibrotic effect of investigational drugs in TGF-β induced lung fibrosis organoid model.
Reference paper: Cell Death Discov. 2021 Mar 15;7(1):48)

Applications:

* Efficacy test of anti-fibrotic drugs at early drug discovery (hit to lead)
* Optimal dose screening for preclinical study.

Heart Failure assay

NEXEL has developed self-organizing cardiac organoids (COs) from hiPSCs with a vascular network and extracellular matrix environment that resembles human heart tissue.
Providing drug-induced heart failure upon drug treatment in the organoid system (acute and chronic effects).

Applications:

* Proarrhythmic risk screening at early drug discovery (hit to lead).
* Optimal dose screening for preclinical study.
* Cardiac safety pharmacology study for IND filing of investigational drugs (after adoption of new ICH E14/S7B).

Cardiomyocyte Characterization

Providing validation service for customer-developed cardiomyocytes (iPSC-derived or others).
Evaluating base electrical properties of the cardiomyocytes with drug responses against the reference drugs (3 ~ 4 drugs).

Applications:

* For cardiomyocytes developers in laboratories and industries.

Cardiac safety against the liver metabolite

!!Coming soon!!

Assay Categories Methods Systems Testing model Data sets Lead time
Cardiac safety (Predicting proarrhythmic risk of investigational drugs) Electrical signal (Extracellular field potential) effects based evaluation Axion Maestro / Nanion CardioExcyte 96 Human iPSC-derived Cardiomyocytes (Cardiosight®-S) FPDcF, Beat rate, Spike amplitude, Beat irregularity, Conductivity propagation (Axion Maestro only) 1 - 2 months
Cardiac contractility Impedance based evaluation Nanion FLEXcyte 96 Human iPSC-derived Cardiomyocytes (Cardiosight®-S) Beat rate, Amplitude, Rising time, Falling time, Beat irregularity 1 month
Skeletal muscle contractility Magnetic force based evaluation CuriBio Mantarray 3D Engineered human muscle tissue force frequency, rate of contraction / relaxation, time to max. twitch, max. twitch amplitude, full width at half max 1 - 2 months
Calcium transient Fluorescence image based evaluation Molecular Device Microplate reader / NIS element software Human iPSC-derived Cardiomyocytes (Cardiosight®-S) Beat rate, peak to peak analysis, Amplitude 1 - 2 months
Lung toxicity PCR, Western Blot, ELISA Varies Human iPSC-derived lung organoids Live and Dead, Changes in Lung functional markers, Changes in inflammatory factors 2 months
Lung fibrosis PCR, Western Blot Varies Fibrosis induced alveolar organoids (human iPSC-derived) Fibrosis markers 2 months
Heart Failure assay Fluorescence image based evaluation Immunocytochemistry NIS element software Human iPSC-derived multicellular cardiac organoids Beat rate, peak to peak analysis, Amplitude, fibrosis marker 2 ~ 3 months
Cardiomyocyte Characterization Baseline properties of iPSC-CM Electrophysiological effects upon reference drug treatment Axion Maestro Customer providing cardiomyocytes Beat rate, FPDcF, Spike amplitude, Drug response 1 ~ 2 months
Cardiac safety against the liver metabolites coming soon coming soon coming soon coming soon TBD
  • logoCONTACT

    Contact Information

    • Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)

    • Business Registration No.: 109-86-37282
    • CEO: Choongseong Han

    • Tel: +82-2-2088-8886
    • Fax: +82-2-2088-8884
    • E-mail: support@nexel.co.kr